Trials / Completed
CompletedNCT00264667
Study In Patients With Dyslipidaemia
A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 290 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study in patients with dyslipidaemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW677954 |
Timeline
- Start date
- 2005-12-01
- Completion
- 2007-06-01
- First posted
- 2005-12-13
- Last updated
- 2016-10-28
Locations
50 sites across 13 countries: Argentina, Australia, Chile, Costa Rica, India, Latvia, Mexico, New Zealand, Pakistan, Romania, Russia, Slovakia, Spain
Source: ClinicalTrials.gov record NCT00264667. Inclusion in this directory is not an endorsement.